Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18

Laboratory Investigation

Volumn 84, Issue 7, 2004, Pages 894-907

  Omara Opyene, Archangel Levi ^a   Qiu, Jingxin ^a   Shah, Girish V ^b   Iczkowski, Kenneth A ^a,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CD44; Matrigel invasion; Muc18; Prostate cancer; RNA interference

Indexed keywords

DNA FRAGMENT; DOUBLE STRANDED RNA; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HERMES ANTIGEN; MATRIGEL; MUCIN; MUCIN 18; UNCLASSIFIED DRUG;

ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CELL ADHESION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; METASTASIS; MOLECULAR CLONING; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIGENS, CD; ANTIGENS, CD146; ANTIGENS, CD44; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; NEURAL CELL ADHESION MOLECULES; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 3042547725     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700112     Document Type: Article

References (51)

1. Iwase A, Shen R, Navarro D, et al. Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem 2004;279:11898-11905.
2. Bourguignon LYW, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 1998;3:D637-D649.
3. Goodison S, Tarin D. Clinical implications of anomalous CD44 gene expression in neoplasia. Front Biosci 1998;3:e89-e109.
4. Martyn V, Bell D, Jackson F, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-12164.
5. Okamoto I, Morisaki T, Sasaki J, et al. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. J Natl Cancer Inst 1998;90:307-315.
6. Okamoto I, Tsuiki H, Kenyon LC, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 2002;160:441-447.
7. Okamoto I, Kawano Y, Murakami D, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 2001;155:755-762.
8. Murakami D, Okamoto I, Nagano O, et al. Presenilin-dependent gamma-secretase activity medicates the intramembranous cleavage of CD44. Oncogene 2003;22:1511-1516.
9. Gansauge F, Gansauge S, Rau B, et al. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma. Cancer 1997;80:1733-1739.
10. Taylor DD, Gercel-Taylor C, Gall SA. Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. J Soc Gynecol Invest 1996;3:289-294.
11. Iczkowski, KA, Pantazis CG, Collins J. The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol 1997;6:119-129.
12. Nagabhushan M, Pretlow TG, Guo YJ, et al. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 1996;106:647-651.
13. De Marzo AM, Bradshaw C, Sauvageot J, et al. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998;34:162-168.
14. Rall CJ, Rustgi AK. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 1995;55:1831-1835.
15. Woodman AC, Sugiyama M, Yoshida K, et al. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 1996;149:1519-1530.
16. Bourguignon LY, Zhu H, Shao L, et al. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 1999;43:269-287.
17. Roca X, Mate JL, Ariza A, et al. CD44 isoform expression follows two alternative splicing pathways in breast tissue. Am J Pathol 1998;153:183-190.
18. Franzmann EJ, Weed DT, Civantos FJ, et al. A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression. Otolaryngol Head Neck Surg 2001;124:426-432.
19. Terpe H-J, Storkel S, Zimmer U, et al. Expression of CD44 isoforms in renal cell tumors. Am J Pathol 1996;148:453-463.
20. Christ O, Gunthert U, Haas R, et al. Importance of CD44v7 isoforms for homing and seeding of hematopoietic progenitor cells. J Leukoc Biol 2001;69:343-352.
21. Mortegani MP, Del Prete F, Gasbarri A, et al. Structural variability of CD44 molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products. Am J Pathol 1999;154:291-300.
22. Miyake H, Okamoto I, Hara I, et al. Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CDv8-v10/CD44v10 competitive RT-PCR. Int J Cancer 1998;18:560-564.
23. Yamaguchi A, Urano T, Goi T, et al. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J. Clin Oncol 1996;14:1122-1127.
24. Dhir R, Thomas A, Krill D, et al. Immunohistochemical detection of isoforms of CD44 in metastatic and organ confined prostatic adenocarcinoma. Mod Pathol 1998;11:80A (Abstract).
25. Iczkowski KA, Bai S, Pantazis CG. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 2003;23:3129-3140.
26. Wu G-J, Wu M-WH, Wang S-W, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001;279:17-31.
27. Wu G-J, Varma VA, Wu M-WH, et al. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 2001;48:305-315.
28. Tomita K, van Boknoven A, van Leenders GJLH, et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60:3650-3654.
29. Burger MJ, Tebay MA, Keith PA, et al. Expression analysis of δ-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 2002;100:228-237.
30. Sers C, Riethmuller G, Johnson JP. Muc18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res 1994;54:5689-5694.
31. sα) in proliferation of PC-3M prostate cancer cells. Int J Cancer 2001;91:46-54.
32. sαQL)-medicated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 1999;18:3376-3382.
33. Yoshida K, Goodison S, Sugino T, et al. Semiquantitative detection of abnormal CD44 transcripts in colon carcinomas by reverse transcription- polymerase chain reaction enzyme-linked immunosorbent assay (RT-PCR ELISA). Mol Diagn 1996;1:167-173.
34. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-12164.
35. Paddison PJ, Caudy MA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-958.
36. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003;100:2014-2018.
37. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
38. Matsumura Y, Sugiyama M, Matsumura S, et al. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 1995;177:11-20.
39. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nature Rev 2002;3:737-747.
40. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
41. Wong LS, Cantrill JE, Odogwu S, et al. Detection of circulating tumour cells and nodal metastasis by reverse transcriptase-polymerase chain reaction technique. Br J Surg 1997;84:834-839.
42. Goodison S, Yoshida K, Sugino T, et al. Rapid analysis of distinctive CD44 RNA splicing preferences that characterize colonic cancer. Cancer Res 1997;57:3140-3144.
43. Yoshida K, Bolodeoku J, Sugino T, et al. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res 1995;55:4273-4277.
44. Holzer G, Kittl E, Pfandelsteiner T, et al. Concentration of soluble CD44 standard and soluble CD44 variant v5 in the serum of patients with malignant bone tumors. Med Pediatr Oncol 2003;40:64-65.
45. Kopp R, Classen S, Wolf H, et al. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res 2001;21:2995-3000.
46. Haegel-Kronenberger H, de la Salle H, Bohbot A, et al. Adhesive and/or signaling functions of CD44 isoforms in human dendritic cells. J Immunol 1998;161:3902-3911.
47. Harn HJ, Shen KL, Liu CA, et al. Hyaluronate binding assay study of transfected CD44 v4-v7 isoforms into the human gastric carcinoma cell line SC-M1. J Pathol 1998;184:291-296.
48. Van Driel M, Gunthert U, van Kessel AC, et al. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stem cells. Leukemia 2002;16:135-143.
49. Yoshinari C, Mizusawa N, Byers HR, et al. CD44 variant isoform CD44v10 expression of human melanoma cell lines is upregulated by hyaluronate and correlates with migration. Melanoma Res 1999;9:223-231.
50. Singleton PA, Bourguignon LY. CD44v10 interaction with Rho-kinase (ROK) activates inositol 1,4,5-triphosphate (IP3) receptor-mediated Ca2+ signaling during hyaluronan (HA)-induced endothelial cell migration. Cell Motil Cytoskeleton 2002;53:293-316.
51. Iczkowski KA, Pantazis CG, Long J, et al. Expression of calcitonin-like peptide is increased in prostatic adenocarcinoma. J Urol Pathol 1998;8:135-147.